<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Liver transplantation in adults: Deceased donor evaluation and selection
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Liver transplantation in adults: Deceased donor evaluation and selection
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Liver transplantation in adults: Deceased donor evaluation and selection
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Scott J Cotler, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert S Brown, Jr, MD, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kristen M Robson, MD, MBA, FACG
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 01, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The shortage of available donor organs is the major limiting factor in liver transplantation. Optimal deceased donors are generally young, previously healthy persons who develop a fatal brain injury due to causes such as head trauma, intracerebral hemorrhage, or anoxia. The relative shortage of donor livers has led transplant centers to consider organs from marginal donors.
        </p>
        <p>
         This topic will review the selection process for deceased donors and examine donor characteristics associated with recipient outcomes. Patient selection for liver transplantation and for living donor liver transplantation is discussed elsewhere.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4585.html" rel="external">
          "Liver transplantation in adults: Patient selection and pretransplantation evaluation"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4590.html" rel="external">
          "Living donor liver transplantation in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          DONOR EVALUATION
         </span>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Donation after brain death
         </span>
         <span class="headingEndMark">
          —
         </span>
         The United Network for Organ Sharing (UNOS) provides minimum guidelines for organ procurement. The initial evaluation is typically performed by the local organ procurement organization (OPO). The OPO representative verifies that the prospective donor meets the criteria for brain death. Consent for donation is obtained from the potential donor's next of kin. ABO blood type, height, weight, and chest circumference are obtained because recipient matching is based upon blood type and donor organ size.
        </p>
        <p>
         Potential donors with contraindications to donation are excluded. These include nonhepatic malignancy (other than primary brain tumor without ventriculoperitoneal shunt). Previously, anti-human immunodeficiency virus (HIV) seropositivity was an absolute contraindication to donation in the United States. The ban was in part due to concern that transplanting HIV-positive organs into patients with HIV that was well controlled could result in the transfer of resistant HIV to the recipient. However, in 2013, a law was passed that ended a ban on transplanting organs from donors with HIV into HIV-positive recipients because of better HIV therapy as well as high waiting list mortality rates for patients with HIV [
         <a href="#rid1">
          1
         </a>
         ]. Although septicemia is usually considered a contraindication to donation, organs from bacteremic donors have been used successfully. A large retrospective study, for example, showed similar 30-day graft and patient survival in recipients of organs from bacteremic and nonbacteremic donors [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         The OPO representative obtains a medical history, evaluates for a history of substance or alcohol use disorder, and performs a physical examination. Laboratory testing generally includes ABO blood type, complete blood count (CBC), chemistries, prothrombin time (PT), activated partial thromboplastin time (PTT), hepatitis B surface antigen (HBsAg) and anti-hepatitis B core antigen (HBc), anti-hepatitis C virus (HCV), anti-HIV, venereal disease research laboratory (VDRL) or rapid plasma reagin (RPR), and anti-cytomegalovirus (CMV). Blood and urine cultures are performed if the prospective donor was hospitalized for more than 72 hours. OPOs obtain nucleic acid testing (NAT) for HIV and HCV in all increased risk donors to shorten the window period between acquisition of infection and detection by ELISA in order to reduce the risk of transmission to the recipient [
         <a href="#rid3">
          3
         </a>
         ]. Ultrasound imaging or liver biopsy is performed if needed.
        </p>
        <p>
         The local OPO is responsible for donor maintenance until the time of procurement. Vital signs, intake, and output are monitored. Fluids and vasopressors are given as needed to achieve hemodynamic stability. Antibiotics are provided if necessary.
        </p>
        <p>
         Donor care centers are being developed where potential donors who meet criteria for brain death can be transferred to optimize donor management and increase deceased donor organ recovery [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Living donors
         </span>
         <span class="headingEndMark">
          —
         </span>
         This topic is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/4590.html" rel="external">
          "Living donor liver transplantation in adults", section on 'Evaluation of the living liver donor candidate'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          DONOR FACTORS IMPACTING RECIPIENT OUTCOME
         </span>
         <span class="headingEndMark">
          —
         </span>
         Multiple donor and transplant-related characteristics associated with recipient outcomes have been evaluated [
         <a href="#rid5">
          5-14
         </a>
         ]. Comparisons among these studies can be difficult since variable clinical endpoints have been measured, recipients had different forms of underlying liver disease, and because donors are often selected based upon recipient characteristics. Clinical endpoints frequently include the following measures:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Initial graft function
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Primary nonfunction (PNF, ie, graft failure in the immediate postoperative period)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Graft survival
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patient survival
        </p>
        <p>
        </p>
        <p>
         Donor factors that have been associated with adverse outcomes include advanced donor age, donor sex or donor-recipient sex mismatch, moderate to marked hepatic steatosis, and donor hypernatremia.
        </p>
        <p>
         Strategies used to increase available donor livers may affect outcomes. These strategies include adult living donor liver transplantation, donation after circulatory death, the use of hepatitis C virus (HCV)-positive donors for HCV-infected recipients, and use of hepatitis B surface antigen (HBsAg)-positive donors for hepatitis B virus (HBV)-positive and anti-hepatitis B core antigen (HBc)-positive recipients. (See
         <a class="medical medical_review" href="/z/d/html/4590.html" rel="external">
          "Living donor liver transplantation in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4583.html" rel="external">
          "Hepatitis C virus infection in liver transplant candidates and recipients"
         </a>
         .).
        </p>
        <p>
         Although donor characteristics and technical factors will be discussed individually, a combination of risk factors may interact to affect outcomes in individual patients.
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Older age
         </span>
         <span class="headingEndMark">
          —
         </span>
         The use of livers from older donors is common practice [
         <a href="#rid15">
          15
         </a>
         ]. However, livers from older donors can have more initial dysfunction due to ischemic or preservation injury. Delayed nonfunction may occur, necessitating retransplantation. Use of organs felt to be of good quality on careful inspection [
         <a href="#rid16">
          16
         </a>
         ] and minimizing cold ischemia time [
         <a href="#rid17">
          17,18
         </a>
         ] may help to maximize outcomes when livers are used from older donors.
        </p>
        <p>
         Several studies have evaluated the relationship between donor age and recipient outcomes, although data are mixed [
         <a href="#rid5">
          5,7-9,16,17,19-23
         </a>
         ]. An illustrative report included 772 patients who underwent liver transplantation at three centers [
         <a href="#rid16">
          16
         </a>
         ]. Older donors were defined as those aged 50 years and older. Laboratory parameters including alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin, and prothrombin time were higher in recipients with older donors during the first week after transplantation. More importantly, graft survival was reduced at three months in recipients of livers from older donors and this difference persisted to 24 months post-transplant. In multivariate analysis controlling for donor and recipient factors, reduced graft survival was identified only for older donors when the allograft was rated to be poor or fair in quality by the surgeon at the time of harvest. Similar results have been reported in several other series, although the exact donor age associated with worsening outcomes has varied.
        </p>
        <p>
         Other studies suggest that acceptable outcomes can be achieved with older donors [
         <a href="#rid8">
          8,9,17,23-26
         </a>
         ]. Limiting cold ischemia time and degree of steatosis were hypothesized to be important in optimizing the results of transplantation from older donors. In a study using the UNOS database, the five-year cumulative mortality rates were lower for transplant candidates who accepted a liver from an older donor (≥70 years old) compared with matched controls who declined the same offer (23 versus 41 percent) [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
         Prior to the availability of highly effective direct antiviral agents for HCV infection, the use of livers from older donors was a particular concern for recipients with HCV. A single-center study of 124 liver transplants showed that donor age &gt;60 years was associated with the development of severe recurrent HCV and provided an optimal age cutoff to predict an increased risk of HCV-related graft loss [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Hepatic steatosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Donor livers that appear fatty on inspection are biopsied for histologic determination of fat content. Severe macrovesicular steatosis is associated with primary nonfunction [
         <a href="#rid13">
          13,28-33
         </a>
         ]. Outcomes are more variable when organs with moderate steatosis are used. Illustrative studies have shown the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         One study, which analyzed 158 donor liver biopsies, found that moderate fatty change (defined as 30 to 60 percent fat content) was associated with the development of early graft dysfunction [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Another report that categorized donor steatosis as mild (&lt;30 percent), moderate (30 to 60 percent), and massive (&gt;60 percent) found an increased frequency of early graft dysfunction and PNF when donor organs had moderate or massive steatosis [
         <a href="#rid31">
          31
         </a>
         ]. Compared with patients who received livers with mild steatosis, graft survival at one month was slightly lower in those who received livers with moderate steatosis and substantially reduced in those given grafts with massive steatosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A report of 225 consecutive transplants showed that while ≥30 percent donor steatosis was associated with early graft dysfunction, five-year graft survival was similar between patients who received grafts with &lt;30 or &gt;30 percent steatosis [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A retrospective review of the United Network for Organ Sharing Standard Transplant Analysis and Research files examined 5051 liver transplants [
         <a href="#rid35">
          35
         </a>
         ]. At one year, 864 (17 percent) of the grafts had failed. On multivariable analysis, donor livers with greater than 30 percent macrovesicular steatosis had an increased risk of graft loss (relative risk 1.71). Many transplant centers try to avoid using organs with more than 40 percent fatty infiltration and refuse organs with more than 50 percent fat content [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Hypernatremia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Worse outcomes have been reported in liver transplant recipients who receive grafts from donors with hypernatremia. Donor hypernatremia may be a surrogate marker for other factors affecting graft function, including prolonged donor intensive care stay, excessive
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         infusion, and negative water balance resulting from aggressive treatment of cerebral edema, and reduced antidiuretic hormone secretion after brain death. In two reports, the rate of graft loss within one month of transplantation was increased when the donor plasma sodium level exceeded 155 mmol/L [
         <a href="#rid37">
          37,38
         </a>
         ]. Other investigators observed a direct relationship between donor serum sodium levels and degree of early graft dysfunction [
         <a href="#rid39">
          39
         </a>
         ]. Most respondents to a survey of the South-Eastern Organ Procurement Foundation liver transplant centers indicated that the maximum donor serum sodium level that they would accept was 160 to 170 mEq/L [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Hemodynamic instability
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hepatic blood flow decreases with periods of hypotension and the use of high doses of vasopressors predisposing to ischemic liver injury. Early graft dysfunction was observed when donors had hypotension refractory to
         <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">
          dopamine
         </a>
         levels exceeding 15 mcg/kg/min [
         <a href="#rid40">
          40
         </a>
         ]. However, the use of high doses of dopamine was not associated with graft dysfunction when the donor's blood pressure was maintained above 90 mmHg.
        </p>
        <p class="headingAnchor" id="H2027514493">
         <span class="h2">
          Donor-recipient mismatch
         </span>
        </p>
        <p class="headingAnchor" id="H2818677349">
         <span class="h3">
          Sex
         </span>
         <span class="headingEndMark">
          —
         </span>
         Transplantation of livers from female donors was associated with worse outcomes in many, but not all, series [
         <a href="#rid41">
          41-44
         </a>
         ]. Some studies suggest that sex-mismatched transplants in which the liver from a female donor is given to a male recipient may be particularly problematic. As an example, a retrospective evaluation of 994 liver transplants performed over 10 years showed significantly lower graft and patient survival for transplantation of female donors into male recipients compared with other donor-recipient combinations (approximately 56 versus 75 percent two-year graft survival) [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
         A further study of 462 liver transplants with 1.1 to 2.6 years of follow-up found that graft survival was superior with male donors relative to female donors when controlling for other factors [
         <a href="#rid41">
          41
         </a>
         ]. The poorest results were observed with the use of female donors over age 60. A study of pediatric liver transplant patients also documented superior one and five-year graft and patient survival for male-male donor-recipient pairs compared to males who received livers from female donors [
         <a href="#rid43">
          43
         </a>
         ]. The organ allocation system does not take the donor's or recipient's sex into account in distributing livers since other considerations are more important.
        </p>
        <p class="headingAnchor" id="H2839030503">
         <span class="h3">
          ABO compatibility
         </span>
         <span class="headingEndMark">
          —
         </span>
         Livers are routinely matched by ABO blood type (ABO identical), although mismatched organs have been used in extreme circumstances. Mismatched organs may either be ABO compatible (eg, an organ from a donor who is type O going to a recipient who is type B) or ABO incompatible (eg, an organ from an donor who is type A going to a recipient who is type B). A retrospective study of 234 liver transplants found that two-year graft survival was 30 percent in 17 ABO-incompatible emergency transplants compared with 76 percent in 55 ABO-compatible emergency transplants and 80 percent in 162 ABO-compatible elective transplants [
         <a href="#rid45">
          45
         </a>
         ]. Compared with ABO-compatible transplants, antibody mediated rejection (AMR), T-cell mediated rejection, arterial thrombosis, and biliary complications were more common in ABO-incompatible recipients. These data suggest that ABO incompatibility (and not a need for emergency transplantation) was the major reason for graft loss, although the urgent nature of the transplant and severe illness likely had a role as well. Registry data from Europe showed that the risk of mortality was increased nearly two times in recipients of ABO-incompatible livers [
         <a href="#rid46">
          46
         </a>
         ]. However, good outcomes have been reported among recipients with blood type O who receive an organ from a donor with blood type A2 with overall and graft survival rates that are similar to those seen when a recipient with blood type O receives an ABO-compatible organ [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
         Many centers use ABO-incompatible livers in emergency situations such as fulminant hepatic failure when an ABO-identical or compatible organ is unavailable, with the understanding that retransplantation will be required in some patients. In such cases, perioperative plasmapheresis, intensive induction immunosuppression, and prostaglandin E1 administration may reduce the development of severe acute rejection [
         <a href="#rid48">
          48,49
         </a>
         ].
        </p>
        <p>
         There have also been successful elective transplantations of ABO-incompatible organs from living donors. In a series of 22 recipients of ABO-incompatible organs, overall patient and graft survival were 100 percent after a mean follow-up of 10 months (range 3 to 21 months) [
         <a href="#rid50">
          50
         </a>
         ]. All of the patients received
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         two weeks prior to transplantation and also underwent plasma exchange with blood group AB fresh frozen plasma every other day prior to transplantation. Plasma exchange transfusion was continued until the IgM and IgG isoagglutinin titers that corresponded to the donor ABO blood group were ≤1:8. During the first two weeks following transplantation, plasma exchange transfusion was repeated if the titers were &gt;1:32. In a retrospective study of 104 ABO-incompatible living donor transplant patients who received rituximab desensitization, 19 recipients developed AMR [
         <a href="#rid51">
          51
         </a>
         ]. Independent risk factors for AMR were low MELD score (&lt;13) and high anti-ABO IgM titer prior to rituximab therapy. Patients with both risk factors had reduced survival; only two of 10 recipients survived beyond five years post-transplant.
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          TECHNICAL FACTORS
         </span>
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Cold ischemia time
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prolonged cold ischemia time (ie, greater than 12 hours) may impact donor organ viability and graft survival. Donor livers are typically preserved in University of Wisconsin storage solution cooled to 0 to 4º C after harvesting. Cold preservation leads to liver injury over time, and the duration of cold ischemia time (CIT) affects recipient outcomes.
        </p>
        <p>
         Early studies showed that CIT exceeding 18 to 20 hours was associated with increased rates of early graft dysfunction, PNF [
         <a href="#rid30">
          30
         </a>
         ], and need for retransplantation within 14 days [
         <a href="#rid52">
          52
         </a>
         ]. Subsequent reports showed a benefit for maintaining CIT less than 12 hours. Better initial graft function, reduced frequency of PNF, and superior graft and patient survival were observed with CIT less than 12 hours in an analysis that excluded emergency transplantation [
         <a href="#rid53">
          53
         </a>
         ]. Data from a large European registry indicated that the risk of recipient mortality was stable for CIT up to 12 hours and increased with longer preservation times [
         <a href="#rid46">
          46
         </a>
         ]. In multivariate analysis, there was a negative interaction between CIT exceeding 12 hours and recipient age greater than or equal to 60 years, and CIT exceeding 12 hours and status as a previous transplant recipient with graft failure.
        </p>
        <p>
         Other studies found that CIT exceeding 12 hours was associated with an increased rate of biliary complications, such as intrahepatic strictures [
         <a href="#rid54">
          54
         </a>
         ]. Most centers try to limit CIT to less than 12 hours, particularly in the presence of other donor or recipient characteristics that can adversely affect transplant outcomes.
        </p>
        <p class="headingAnchor" id="H3492341849">
         <span class="h1">
          RISK ASSESSMENT INDICES
         </span>
        </p>
        <p class="headingAnchor" id="H4047391447">
         <span class="h2">
          Donor risk index
         </span>
         <span class="headingEndMark">
          —
         </span>
         Data from over 20,000 liver transplants were used to develop a predictive model comprised of donor factors known at the time an organ is offered to quantify the risk of graft failure, and this model is known as the donor risk index (DRI) [
         <a href="#rid55">
          55
         </a>
         ]. The parameters most strongly associated with graft loss include increasing donor age, donation after cardiac death, and use of split/partial grafts. Other risk factors include African American donors, shorter donors, death due to cerebrovascular accident, and causes of brain death other than trauma or anoxia.
        </p>
        <p class="headingAnchor" id="H2419586443">
         <span class="h2">
          Eurotransplant donor risk assessment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Analysis of 4701 deceased donors from Eurotransplant and the European Transplant Registry identified risk factors for graft loss in first time recipients who received a deceased donor liver [
         <a href="#rid56">
          56
         </a>
         ]. Cold ischemia time, highest serum sodium level, cause of donor death, gamma-glutamyl transferase (GGT) level, and female donor sex were predictors of graft loss at three months. In addition, cold ischemia time, GGT, and cause of donor death were associated with 12-month graft loss. The data were used to construct nomograms to allow for rapid assessment of the complex interaction among risk factors in a given donor. When the donor risk index was applied to the dataset, there was limited agreement with the Eurotransplant nomogram (kappa = 0.23). The area under the receiver operating characteristic curve for both predictors was relatively low, indicating the difficulty in defining criteria for extended donors.
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h1">
          APPROACHES TO EXPAND DONOR LIVER SUPPLY
         </span>
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h2">
          Donation after circulatory death
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with an irreversible, catastrophic illness may serve as non-heart-beating donors after withdrawal of care in a controlled hospital setting and after achieving set criteria for cardiac death [
         <a href="#rid57">
          57,58
         </a>
         ]. Such donation is referred to as "donation after circulatory death" (DCD). In the United States, life support is usually withdrawn in the operating room. The patient is observed until the time of death, which is declared by a clinician who is not part of the transplant team. After a waiting period that is generally in the range of five minutes, organ retrieval is initiated with femoral artery cannulation and infusion of cold University of Wisconsin storage solution. Warm ischemia time includes the interval between withdrawal from life support and infusion of University of Wisconsin solution [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
         Use of DCD donor livers could provide a substantial number of needed organs. Outcomes for recipients of DCD donor livers include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patient and graft survival
         </strong>
         — Studies comparing recipients of organs from DCD donors with standard brain-dead deceased donors have been variable, with some showing similar outcomes, while others suggest decreased graft and patient survival following receipt of a DCD donor organ [
         <a href="#rid57">
          57-62
         </a>
         ]. However, many of the studies are limited by the fact that they were not randomized, potentially leading to disparate outcomes that were not the result of the type of donor organ. One series looked at 2572 liver transplantations, 352 of which were from DCD donors [
         <a href="#rid62">
          62
         </a>
         ]. Compared with recipients of standard brain-dead deceased donor organs, recipients of DCD donor organs had higher three-year graft loss (27 versus 18 percent) and higher three-year mortality (19 versus 14 percent). Another retrospective series with 200 liver transplantations from DCD donors and 1828 liver transplantations from brain-dead deceased donors did not find any significant differences in graft or patient survival between the groups at one, three, or five years [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Donor factors associated with graft failure have included indicators of prolonged warm ischemia time, such as a mean arterial pressure lower than 60 mmHg for more than 20 minutes after the withdrawal of life support and longer cold ischemia times (&gt;6 hours in one study) [
         <a href="#rid61">
          61,63
         </a>
         ]. The use of DCD liver grafts with moderate macrosteatosis (30 to 60 percent) was associated with adverse outcomes including primary non-function and early allograft dysfunction [
         <a href="#rid64">
          64
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Many centers avoid using DCD livers from older donors (eg, donor age &gt;50 years). However, a study from the UK transplant registry of experienced centers using careful selection of donors and recipients showed no significant differences in 5-year graft survival between DCD donor age &gt;70 years compared with donor age &lt;70 years [
         <a href="#rid65">
          65
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Recipient factors associated with reduced DCD graft survival reflected severity of illness, functional reserve, and complexity of the operation. As an example, recipient factors included in the UK-DCD risk score were age &gt;60 years, MELD score &gt;25, and retransplantation [
         <a href="#rid66">
          66
         </a>
         ]. The UK-DCD risk score was developed to match DCD donors and recipients to optimize outcomes [
         <a href="#rid61">
          61,63
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Biliary complications
         </strong>
         — The use of DCD donors is associated with an increased risk of ischemic cholangiopathy, manifested by diffuse nonanastomotic biliary strictures in the absence of hepatic artery thrombosis. Ischemia-reperfusion injury can cause bile duct injury and subsequent fibrotic narrowing and scarring of the biliary tree after transplantation [
         <a href="#rid67">
          67,68
         </a>
         ]. Indicators of prolonged functional warm ischemia time (eg, longer asystole to cross clamp time) are associated with biliary complications [
         <a href="#rid69">
          69
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Single-center studies from transplantation programs that are experienced in the use of DCD livers have reported ischemic cholangiopathy in approximately five percent of recipients of DCD liver grafts [
         <a href="#rid70">
          70,71
         </a>
         ]. However, prior studies including recipients of DCD donor livers reported higher rates of post-transplant biliary complications that ranged from 12 to 60 percent [
         <a href="#rid60">
          60,61,72
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Strategies to expand the use of DCD donor livers while minimizing the risk of ischemic cholangiopathy for recipients of such liver grafts include an organ preservation technique using hypothermic oxygenated machine perfusion [
         <a href="#rid73">
          73,74
         </a>
         ]. In a randomized trial of 156 patients who were transplanted with a DCD liver graft, conventional cold storage followed by hypothermic machine perfusion of the liver graft prior to implantation resulted in a lower risk of nonanastomotic biliary strictures within six months after transplant compared with cold storage alone (6 versus 18 percent; risk ratio 0.36, 95% CI 0.14-0.94) [
         <a href="#rid73">
          73
         </a>
         ]. In addition, patients in the machine-perfusion group had lower rates of endoscopic or percutaneous interventions for nonanastomotic biliary strictures (4 versus 14 percent), although statistical analysis was not provided. Notably, the rate of ischemic cholangiopathy in the hypothermic machine perfusion group (6 percent) was similar to rates reported in some studies of DCD donor livers without machine perfusion [
         <a href="#rid70">
          70,71,75
         </a>
         ]. Additional trials are needed to assess the short- and long-term impact of novel preservation techniques such as hypothermic machine perfusion on outcomes for recipients of DCD donor livers. (See
         <a class="local">
          'Machine liver perfusion'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1115183162">
         <span class="h2">
          Hepatitis C virus-positive donors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Given the high success rate of direct-acting antiviral (DAA) therapy and limited supply of donor livers, use of livers from HCV-viremic donors for HCV-positive recipients is common. Increasing evidence has suggested that using organs from HCV viremic donors for HCV-negative recipients followed by DAA treatment in the early post-transplant period is an overall effective and safe strategy [
         <a href="#rid76">
          76,77
         </a>
         ]. Outcomes in recipients of HCV-positive liver grafts are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4583.html" rel="external">
          "Hepatitis C virus infection in liver transplant candidates and recipients"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h2">
          Hepatitis B virus-positive donors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Transplantation of organs from donors with serologic markers for past HBV infection has the potential to increase the donor pool, particularly in regions where HBV carriers are frequent (such as the Mediterranean region and Asia). It is generally recommended that grafts from hepatitis B core antibody (anti-HBc)-positive donors should be offered to hepatitis B surface antigen (HBsAg)-positive recipients, although recipients who lack HBV markers may also be eligible provided that they receive antiviral prophylaxis post-transplantation. Antiviral prophylaxis for reducing the risk of donor-related HBV transmission to the recipient is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4584.html" rel="external">
          "Liver transplantation in adults: Preventing hepatitis B virus infection in liver transplant recipients"
         </a>
         .)
        </p>
        <p>
         More controversial is the use of livers from donors who are HBsAg-positive. Transplantation of such grafts has been described [
         <a href="#rid78">
          78,79
         </a>
         ] but should probably not be offered to patients who are HBsAg-negative or to recipients who have concurrent HDV infection since such patients may develop severe HDV-related disease after transplant [
         <a href="#rid80">
          80
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3417493588">
         <span class="h2">
          Machine liver perfusion
         </span>
         <span class="headingEndMark">
          —
         </span>
         Both hypothermic oxygenated perfusion (HOPE) and ex-vivo normothermic machine perfusion (NMP) are being studied as techniques to expand the donor pool by limiting the deleterious effects of cold ischemia on extended criteria grafts such as DCD liver grafts and livers with steatosis [
         <a href="#rid73">
          73,81-84
         </a>
         ] (see
         <a class="local">
          'Donation after circulatory death'
         </a>
         above):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         HOPE has been studied as a method to improve outcomes with use of extended criteria donors and may protect against ischemic cholangiopathy [
         <a href="#rid73">
          73,81
         </a>
         ]. A phase 3 randomized trial assessed the impact of cold storage followed by HOPE compared with cold storage alone in 170 liver transplant recipients who received a donor brain death (DBD) liver [
         <a href="#rid85">
          85
         </a>
         ]. Within one year following transplantation, there were no significant differences between the groups in rates of having at least one Clavian grade &gt;III complication or in other outcomes such as post-transplant laboratory values, duration of intensive care and hospital stay, and graft and patient survival [
         <a href="#rid85">
          85,86
         </a>
         ]. However, the HOPE group had lower rates of Clavian grade &gt;IIIb complications and liver complication-related graft loss.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Studies have demonstrated that NMP allows for assessment of graft function including metabolic and perfusion parameters and bile flow prior to implantation [
         <a href="#rid82">
          82,83,87,88
         </a>
         ]. Use of a normothermic ex-vivo circuit has the potential to predict graft viability in an effort to minimize primary graft nonfunction with use of extended criteria donor livers [
         <a href="#rid89">
          89,90
         </a>
         ]. In a trial comparing NMP for 4 to 24 hours with conventional cold storage in 266 donor livers, there were no significant differences in the rates of early allograft dysfunction (EAD) or graft survival between the donor groups [
         <a href="#rid89">
          89
         </a>
         ]. In subgroup analysis, the NMP group had a lower rate of EAD in DCD livers (23 versus 45 percent) and in livers in the highest risk quartile by donor risk (19 versus 33 percent).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h1">
          SPLIT-LIVER TRANSPLANTATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Splitting livers into right and left lobes for transplantation has been investigated as a way to increase the supply of donor organs. Studies have looked at allocating the split organ to an adult and a pediatric recipient or to two adults.
        </p>
        <p>
         A working group appointed by the American Society of Transplant Surgeons and the American Society of Transplantation has advocated the institution of a national policy for splitting appropriate donor livers into left lateral and extended right grafts for transplantation into a pediatric and an adult recipient, respectively [
         <a href="#rid91">
          91
         </a>
         ]. Many suitable livers are reduced in size for pediatric transplantation, and are not split with an adult recipient. According to the analysis of the working group, approximately 20 percent of donors could be split, increasing the total number of liver transplant recipients in the United States by up to 1000 annually. Outcomes of in situ liver splitting for adult/child pairs have been comparable to whole graft transplantation.
        </p>
        <p>
         In a study of 106 split liver transplantations, adult 1-, 5-, and 10-year survival rates were 93, 77, and 73 percent, respectively, with graft survival rates of 89, 76, and 65 percent, respectively [
         <a href="#rid92">
          92
         </a>
         ]. For children, 1-, 5-, and 10-year survival rates were 84, 75, and 69 percent, respectively, with graft survival rates of 77, 63, and 57 percent, respectively.
        </p>
        <p>
         Splitting the organ between two adults was examined in a retrospective study of 42 patients who received split liver transplantations [
         <a href="#rid93">
          93
         </a>
         ]. One lobe of the liver went to the patient on the waiting list with the same blood type and the highest Model for End-stage Liver Disease score, provided the graft-recipient weight ratio (GRWR) for one of the lobes was at least 0.8 percent. The second lobe went to a recipient with the same blood type in whom the GRWR was 0.8 percent or more. The three-month, one-year, three-year, and five-year survival rates were 76, 71, 69, and 69 percent, respectively. Survival rates were similar to those seen in patients who received living donor transplantations during the same period.
        </p>
        <p class="headingAnchor" id="H3472382635">
         <span class="h1">
          EXTENDED CRITERIA LIVER GRAFT OUTCOMES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The use of marginal or extended criteria liver grafts may lower the risk of mortality on the liver transplant waiting list without impacting patient or graft survival. In an 18-year study of over 2000 liver transplant recipients from a single transplant program, there was no significant difference in rates of one- three- and five-year patient survival for patients receiving marginal liver grafts compared with those receiving standard grafts during the second nine year period [
         <a href="#rid94">
          94
         </a>
         ]. Marginal liver grafts included those with any of the following characteristics:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Liver donor age &gt;70 years (see
         <a class="local">
          'Older age'
         </a>
         above)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Livers discarded regionally and shared nationally
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Livers from HCV-positive donors
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Livers with cold ischemia time &gt;12 hours (see
         <a class="local">
          'Cold ischemia time'
         </a>
         above)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Livers from donation after circulatory death donors (see
         <a class="local">
          'Donation after circulatory death'
         </a>
         above)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Livers with &gt;30 percent steatosis (see
         <a class="local">
          'Hepatic steatosis'
         </a>
         above)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Livers split between two recipients (see
         <a class="local">
          'Split-liver transplantation'
         </a>
         above)
        </p>
        <p>
        </p>
        <p>
         The mortality rate for patients who were waitlisted at the transplant program using marginal liver grafts was lower compared with the national waitlist mortality rate (19 versus 24 percent).
        </p>
        <p class="headingAnchor" id="H2095425841">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/113977.html" rel="external">
          "Society guideline links: Liver transplantation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Background
         </strong>
         – The United Network for Organ Sharing provides minimum guidelines for organ procurement. The initial evaluation is typically performed by the local organ procurement organization (OPO). The OPO representative verifies that the prospective donor meets the criteria for brain death. Consent for donation is obtained from the potential donor's next of kin. (See
         <a class="local">
          'Donation after brain death'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Donor factors impacting recipient outcome
         </strong>
         – Donor characteristics that are associated with an adverse effect on graft function and/or graft survival include "donation after circulatory death" (DCD), advanced donor age, moderate to marked hepatic steatosis, and donor hypernatremia. (See
         <a class="local">
          'Donor factors impacting recipient outcome'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The number and severity of donor risk factors is considered in evaluating prospective donors and risk assessment indices have been developed. (See
         <a class="local">
          'Risk assessment indices'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Approaches to expand the donor liver supply
         </strong>
         – A shortage of donor livers has led to alternative approaches such as the use of DCD donors and hepatitis C virus (HCV)-positive donors to increase the donor organ supply. (See
         <a class="medical medical_review" href="/z/d/html/4583.html" rel="external">
          "Hepatitis C virus infection in liver transplant candidates and recipients"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Strategies such as hypothermic machine perfusion of DCD donor livers are being studied to expand the donor supply while minimizing the risk of recipient complications (eg, ischemic cholangiopathy). (See
         <a class="local">
          'Approaches to expand donor liver supply'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Judicious use of extended criteria liver grafts may lower the risk of mortality for patients on the liver transplant waiting list without impacting patient survival or graft function or survival. (See
         <a class="local">
          'Extended criteria liver graft outcomes'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Malani PN. New law allows organ transplants from deceased HIV-infected donors to HIV-infected recipients. JAMA 2013; 310:2492.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freeman RB, Giatras I, Falagas ME, et al. Outcome of transplantation of organs procured from bacteremic donors. Transplantation 1999; 68:1107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kucirka LM, Alexander C, Namuyinga R, et al. Viral nucleic acid testing (NAT) and OPO-level disposition of high-risk donor organs. Am J Transplant 2009; 9:620.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marsolais P, Durand P, Charbonney E, et al. The First 2 Years of Activity of a Specialized Organ Procurement Center: Report of an Innovative Approach to Improve Organ Donation. Am J Transplant 2017; 17:1613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Condron SL, Heneghan MA, Patel K, et al. Effect of donor age on survival of liver transplant recipients with hepatitis C virus infection. Transplantation 2005; 80:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cuende N, Miranda B, Cañón JF, et al. Donor characteristics associated with liver graft survival. Transplantation 2005; 79:1445.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sánchez-Perez B, Santoyo J, Fernández-Aguilar JL, et al. Preoperative factors and models predicting mortality in liver transplantation. Transplant Proc 2005; 37:1499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zapletal Ch, Faust D, Wullstein C, et al. Does the liver ever age? Results of liver transplantation with donors above 80 years of age. Transplant Proc 2005; 37:1182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pirenne J, Monbaliu D, Van Gelder F, et al. Liver transplantation using livers from septuagenarian and octogenarian donors: an underused strategy to reduce mortality on the waiting list. Transplant Proc 2005; 37:1180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Santori G, Andorno E, Morelli N, et al. Impact of ischemia/reperfusion on transplanted livers procured from elderly cadaveric donors. Transplant Proc 2004; 36:2909.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Totsuka E, Fung U, Hakamada K, et al. Analysis of clinical variables of donors and recipients with respect to short-term graft outcome in human liver transplantation. Transplant Proc 2004; 36:2215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moore DE, Feurer ID, Speroff T, et al. Impact of donor, technical, and recipient risk factors on survival and quality of life after liver transplantation. Arch Surg 2005; 140:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fernández-Merino FJ, Nuño-Garza J, López-Hervás P, et al. Impact of donor, recipient, and graft features on the development of primary dysfunction in liver transplants. Transplant Proc 2003; 35:1793.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corradini SG, Elisei W, De Marco R, et al. Preharvest donor hyperoxia predicts good early graft function and longer graft survival after liver transplantation. Liver Transpl 2005; 11:140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kauffman HM, McBride MA, Rosendale JD, et al. Trends in organ donation, recovery and disposition: UNOS data for 1988-1996. Transplant Proc 1997; 29:3303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoofnagle JH, Lombardero M, Zetterman RK, et al. Donor age and outcome of liver transplantation. Hepatology 1996; 24:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grande L, Rull A, Rimola A, et al. Outcome of patients undergoing orthotopic liver transplantation with elderly donors (over 60 years). Transplant Proc 1997; 29:3289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Emre S, Schwartz ME, Altaca G, et al. Safe use of hepatic allografts from donors older than 70 years. Transplantation 1996; 62:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yersiz H, Shaked A, Olthoff K, et al. Correlation between donor age and the pattern of liver graft recovery after transplantation. Transplantation 1995; 60:790.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Washburn WK, Johnson LB, Lewis WD, Jenkins RL. Graft function and outcome of older (&gt; or = 60 years) donor livers. Transplantation 1996; 61:1062.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marino IR, Doyle HR, Doria C, et al. Outcome of liver transplantation using donors 60 to 79 years of age. Transplant Proc 1995; 27:1184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Busquets J, Xiol X, Figueras J, et al. The impact of donor age on liver transplantation: influence of donor age on early liver function and on subsequent patient and graft survival. Transplantation 2001; 71:1765.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haugen CE, Bowring MG, Holscher CM, et al. Survival benefit of accepting livers from deceased donors over 70 years old. Am J Transplant 2019; 19:2020.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chapman WC, Vachharajani N, Collins KM, et al. Donor Age-Based Analysis of Liver Transplantation Outcomes: Short- and Long-Term Outcomes Are Similar Regardless of Donor Age. J Am Coll Surg 2015; 221:59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paterno F, Wima K, Hoehn RS, et al. Use of Elderly Allografts in Liver Transplantation. Transplantation 2016; 100:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fernandes MR, Waisberg DR, Lima MRD, et al. Septuagenarian Donors and Recipients in Deceased Donor Liver Transplantation: A Brazilian Single Center Experience and Literature Review. Transplant Proc 2022; 54:1329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rayhill SC, Wu YM, Katz DA, et al. Older donor livers show early severe histological activity, fibrosis, and graft failure after liver transplantation for hepatitis C. Transplantation 2007; 84:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Todo S, Demetris AJ, Makowka L, et al. Primary nonfunction of hepatic allografts with preexisting fatty infiltration. Transplantation 1989; 47:903.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Alessandro AM, Kalayoglu M, Sollinger HW, et al. The predictive value of donor liver biopsies on the development of primary nonfunction after orthotopic liver transplantation. Transplant Proc 1991; 23:1536.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ploeg RJ, D'Alessandro AM, Knechtle SJ, et al. Risk factors for primary dysfunction after liver transplantation--a multivariate analysis. Transplantation 1993; 55:807.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adam R, Reynes M, Johann M, et al. The outcome of steatotic grafts in liver transplantation. Transplant Proc 1991; 23:1538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Afonso RC, Saad WA, Parra OM, et al. Impact of steatotic grafts on initial function and prognosis after liver transplantation. Transplant Proc 2004; 36:909.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verran D, Kusyk T, Painter D, et al. Clinical experience gained from the use of 120 steatotic donor livers for orthotopic liver transplantation. Liver Transpl 2003; 9:500.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Angele MK, Rentsch M, Hartl WH, et al. Effect of graft steatosis on liver function and organ survival after liver transplantation. Am J Surg 2008; 195:214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spitzer AL, Lao OB, Dick AA, et al. The biopsied donor liver: incorporating macrosteatosis into high-risk donor assessment. Liver Transpl 2010; 16:874.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Broughan TA, Douzdjian V. Donor liver selection. The South-Eastern Organ Procurement Foundation Liver Committee. Am Surg 1998; 64:785.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Figueras J, Busquets J, Grande L, et al. The deleterious effect of donor high plasma sodium and extended preservation in liver transplantation. A multivariate analysis. Transplantation 1996; 61:410.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Briceño J, Pera-Rojas C, Solorzano G, et al. Use of high-risk liver donors for urgent and elective liver transplantation. Transplant Proc 1999; 31:440.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Avolio AW, Agnes S, Magalini SC, et al. Importance of donor blood chemistry data (AST, serum sodium) in predicting liver transplant outcome. Transplant Proc 1991; 23:2451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mor E, Klintmalm GB, Gonwa TA, et al. The use of marginal donors for liver transplantation. A retrospective study of 365 liver donors. Transplantation 1992; 53:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marino IR, Doyle HR, Aldrighetti L, et al. Effect of donor age and sex on the outcome of liver transplantation. Hepatology 1995; 22:1754.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brooks BK, Levy MF, Jennings LW, et al. Influence of donor and recipient gender on the outcome of liver transplantation. Transplantation 1996; 62:1784.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Francavilla R, Hadzic N, Heaton ND, et al. Gender matching and outcome after pediatric liver transplantation. Transplantation 1998; 66:602.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berrevoet F, Hesse UJ, de Laere S, et al. Impact of donor and recipient gender on liver transplantation. Transplant Proc 1997; 29:3431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gugenheim J, Samuel D, Reynes M, Bismuth H. Liver transplantation across ABO blood group barriers. Lancet 1990; 336:519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adam R, Cailliez V, Majno P, et al. Normalised intrinsic mortality risk in liver transplantation: European Liver Transplant Registry study. Lancet 2000; 356:621.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kluger MD, Guarrera JV, Olsen SK, et al. Safety of blood group A2-to-O liver transplantation: an analysis of the United Network of Organ Sharing database. Transplantation 2012; 94:526.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mor E, Skerrett D, Manzarbeitia C, et al. Successful use of an enhanced immunosuppressive protocol with plasmapheresis for ABO-incompatible mismatched grafts in liver transplant recipients. Transplantation 1995; 59:986.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fang WC, Saltzman J, Rososhansky S, et al. Acceptance of an ABO-incompatible mismatched (AB(+) to O(+)) liver allograft with the use of daclizumab and mycophenolate mofetil. Liver Transpl 2000; 6:497.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim JM, Kwon CH, Joh JW, et al. ABO-incompatible living donor liver transplantation is suitable in patients without ABO-matched donor. J Hepatol 2013; 59:1215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tajima T, Hata K, Haga H, et al. Risk factors for antibody-mediated rejection in ABO blood-type incompatible and donor-specific antibody-positive liver transplantation. Liver Transpl 2023; 29:711.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Furukawa H, Todo S, Imventarza O, et al. Effect of cold ischemia time on the early outcome of human hepatic allografts preserved with UW solution. Transplantation 1991; 51:1000.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adam R, Bismuth H, Diamond T, et al. Effect of extended cold ischaemia with UW solution on graft function after liver transplantation. Lancet 1992; 340:1373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Colonna JO 2nd, Shaked A, Gomes AS, et al. Biliary strictures complicating liver transplantation. Incidence, pathogenesis, management, and outcome. Ann Surg 1992; 216:344.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feng S, Goodrich NP, Bragg-Gresham JL, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant 2006; 6:783.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silberhumer GR, Rahmel A, Karam V, et al. The difficulty in defining extended donor criteria for liver grafts: the Eurotransplant experience. Transpl Int 2013; 26:990.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'alessandro AM, Hoffmann RM, Knechtle SJ, et al. Liver transplantation from controlled non-heart-beating donors. Surgery 2000; 128:579.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reich DJ, Munoz SJ, Rothstein KD, et al. Controlled non-heart-beating donor liver transplantation: a successful single center experience, with topic update. Transplantation 2000; 70:1159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Alessandro AM, Fernandez LA, Chin LT, et al. Donation after cardiac death: the University of Wisconsin experience. Ann Transplant 2004; 9:68.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Foley DP, Fernandez LA, Leverson G, et al. Biliary complications after liver transplantation from donation after cardiac death donors: an analysis of risk factors and long-term outcomes from a single center. Ann Surg 2011; 253:817.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taner CB, Bulatao IG, Willingham DL, et al. Events in procurement as risk factors for ischemic cholangiopathy in liver transplantation using donation after cardiac death donors. Liver Transpl 2012; 18:100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Callaghan CJ, Charman SC, Muiesan P, et al. Outcomes of transplantation of livers from donation after circulatory death donors in the UK: a cohort study. BMJ Open 2013; 3:e003287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hong JC, Yersiz H, Kositamongkol P, et al. Liver transplantation using organ donation after cardiac death: a clinical predictive index for graft failure-free survival. Arch Surg 2011; 146:1017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Croome KP, Mathur AK, Mao S, et al. Perioperative and long-term outcomes of utilizing donation after circulatory death liver grafts with macrosteatosis: A multicenter analysis. Am J Transplant 2020; 20:2449.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giorgakis E, Khorsandi SE, Mathur AK, et al. Comparable graft survival is achievable with the usage of donation after circulatory death liver grafts from donors at or above 70 years of age: A long-term UK national analysis. Am J Transplant 2021; 21:2200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schlegel A, Kalisvaart M, Scalera I, et al. The UK DCD Risk Score: A new proposal to define futility in donation-after-circulatory-death liver transplantation. J Hepatol 2018; 68:456.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Vries Y, von Meijenfeldt FA, Porte RJ. Post-transplant cholangiopathy: Classification, pathogenesis, and preventive strategies. Biochim Biophys Acta Mol Basis Dis 2018; 1864:1507.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams WW, Markmann JF. Warming Up to Cold Perfusion. N Engl J Med 2021; 384:1458.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taner CB, Bulatao IG, Perry DK, et al. Asystole to cross-clamp period predicts development of biliary complications in liver transplantation using donation after cardiac death donors. Transpl Int 2012; 25:838.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bohorquez H, Seal JB, Cohen AJ, et al. Safety and Outcomes in 100 Consecutive Donation After Circulatory Death Liver Transplants Using a Protocol That Includes Thrombolytic Therapy. Am J Transplant 2017; 17:2155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mihaylov P, Mangus R, Ekser B, et al. Expanding the Donor Pool With the Use of Extended Criteria Donation After Circulatory Death Livers. Liver Transpl 2019; 25:1198.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maheshwari A, Maley W, Li Z, Thuluvath PJ. Biliary complications and outcomes of liver transplantation from donors after cardiac death. Liver Transpl 2007; 13:1645.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Rijn R, Schurink IJ, de Vries Y, et al. Hypothermic Machine Perfusion in Liver Transplantation - A Randomized Trial. N Engl J Med 2021; 384:1391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Rijn R, van Leeuwen OB, Matton APM, et al. Hypothermic oxygenated machine perfusion reduces bile duct reperfusion injury after transplantation of donation after circulatory death livers. Liver Transpl 2018; 24:655.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Croome KP, Lee DD, Perry DK, et al. Comparison of longterm outcomes and quality of life in recipients of donation after cardiac death liver grafts with a propensity-matched cohort. Liver Transpl 2017; 23:342.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bohorquez H, Bugeaud E, Bzowej N, et al. Liver Transplantation Using Hepatitis C Virus-Viremic Donors Into Hepatitis C Virus-Aviremic Recipients as Standard of Care. Liver Transpl 2021; 27:548.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aqel B, Wijarnpreecha K, Pungpapong S, et al. Outcomes following liver transplantation from HCV-seropositive donors to HCV-seronegative recipients. J Hepatol 2021; 74:873.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loggi E, Micco L, Ercolani G, et al. Liver transplantation from hepatitis B surface antigen positive donors: a safe way to expand the donor pool. J Hepatol 2012; 56:579.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li Z, Hu Z, Xiang J, et al. Use of hepatitis B surface antigen-positive grafts in liver transplantation: a matched analysis of the US National database. Liver Transpl 2014; 20:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Franchello A, Ghisetti V, Marzano A, et al. Transplantation of hepatitis B surface antigen-positive livers into hepatitis B virus-positive recipients and the role of hepatitis delta coinfection. Liver Transpl 2005; 11:922.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schlegel A, Muller X, Kalisvaart M, et al. Outcomes of DCD liver transplantation using organs treated by hypothermic oxygenated perfusion before implantation. J Hepatol 2019; 70:50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ravikumar R, Jassem W, Mergental H, et al. Liver Transplantation After Ex Vivo Normothermic Machine Preservation: A Phase 1 (First-in-Man) Clinical Trial. Am J Transplant 2016; 16:1779.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mergental H, Perera MT, Laing RW, et al. Transplantation of Declined Liver Allografts Following Normothermic Ex-Situ Evaluation. Am J Transplant 2016; 16:3235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guarrera JV, Henry SD, Samstein B, et al. Hypothermic machine preservation in human liver transplantation: the first clinical series. Am J Transplant 2010; 10:372.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schlegel A, Mueller M, Muller X, et al. A multicenter randomized-controlled trial of hypothermic oxygenated perfusion (HOPE) for human liver grafts before transplantation. J Hepatol 2023; 78:783.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240:205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muller X, Schlegel A, Kron P, et al. Novel Real-time Prediction of Liver Graft Function During Hypothermic Oxygenated Machine Perfusion Before Liver Transplantation. Ann Surg 2019; 270:783.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bral M, Gala-Lopez B, Bigam D, et al. Preliminary Single-Center Canadian Experience of Human Normothermic Ex Vivo Liver Perfusion: Results of a Clinical Trial. Am J Transplant 2017; 17:1071.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chapman WC, Barbas AS, D'Alessandro AM, et al. Normothermic Machine Perfusion of Donor Livers for Transplantation in the United States: A Randomized Controlled Trial. Ann Surg 2023; 278:e912.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olthoff KM, Kulik L, Samstein B, et al. Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors. Liver Transpl 2010; 16:943.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Emond JC, Freeman RB Jr, Renz JF, et al. Optimizing the use of donated cadaver livers: analysis and policy development to increase the application of split-liver transplantation. Liver Transpl 2002; 8:863.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vagefi PA, Parekh J, Ascher NL, et al. Outcomes with split liver transplantation in 106 recipients: the University of California, San Francisco, experience from 1993 to 2010. Arch Surg 2011; 146:1052.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee WC, Chan KM, Chou HS, et al. Feasibility of split liver transplantation for 2 adults in the model of end-stage liver disease era. Ann Surg 2013; 258:306.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Halazun KJ, Quillin RC, Rosenblatt R, et al. Expanding the Margins: High Volume Utilization of Marginal Liver Grafts Among &gt;2000 Liver Transplants at a Single Institution. Ann Surg 2017; 266:441.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4592 Version 36.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24346971" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : New law allows organ transplants from deceased HIV-infected donors to HIV-infected recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10551637" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Outcome of transplantation of organs procured from bacteremic donors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19191766" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Viral nucleic acid testing (NAT) and OPO-level disposition of high-risk donor organs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27873446" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : The First 2 Years of Activity of a Specialized Organ Procurement Center: Report of an Innovative Approach to Improve Organ Donation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16003247" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Effect of donor age on survival of liver transplant recipients with hepatitis C virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15912118" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Donor characteristics associated with liver graft survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15866654" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Preoperative factors and models predicting mortality in liver transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15848663" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Does the liver ever age? Results of liver transplantation with donors above 80 years of age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15848662" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Liver transplantation using livers from septuagenarian and octogenarian donors: an underused strategy to reduce mortality on the waiting list.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15686658" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Impact of ischemia/reperfusion on transplanted livers procured from elderly cadaveric donors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15561195" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Analysis of clinical variables of donors and recipients with respect to short-term graft outcome in human liver transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15781792" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Impact of donor, technical, and recipient risk factors on survival and quality of life after liver transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12962797" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Impact of donor, recipient, and graft features on the development of primary dysfunction in liver transplants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15666381" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Preharvest donor hyperoxia predicts good early graft function and longer graft survival after liver transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9414724" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Trends in organ donation, recovery and disposition: UNOS data for 1988-1996.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8707288" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Donor age and outcome of liver transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9414718" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Outcome of patients undergoing orthotopic liver transplantation with elderly donors (over 60 years).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8693547" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Safe use of hepatic allografts from donors older than 70 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7482736" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Correlation between donor age and the pattern of liver graft recovery after transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8623186" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Graft function and outcome of older (&gt;or = 60 years) donor livers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7748258" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Outcome of liver transplantation using donors 60 to 79 years of age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11455256" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : The impact of donor age on liver transplantation: influence of donor age on early liver function and on subsequent patient and graft survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30614634" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Survival benefit of accepting livers from deceased donors over 70 years old.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25872684" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Donor Age-Based Analysis of Liver Transplantation Outcomes: Short- and Long-Term Outcomes Are Similar Regardless of Donor Age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26154390" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Use of Elderly Allografts in Liver Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35690491" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Septuagenarian Donors and Recipients in Deceased Donor Liver Transplantation: A Brazilian Single Center Experience and Literature Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17700157" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Older donor livers show early severe histological activity, fibrosis, and graft failure after liver transplantation for hepatitis C.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2655230" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Primary nonfunction of hepatic allografts with preexisting fatty infiltration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1989280" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : The predictive value of donor liver biopsies on the development of primary nonfunction after orthotopic liver transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8475556" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Risk factors for primary dysfunction after liver transplantation--a multivariate analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1989281" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : The outcome of steatotic grafts in liver transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15194312" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Impact of steatotic grafts on initial function and prognosis after liver transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12740794" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Clinical experience gained from the use of 120 steatotic donor livers for orthotopic liver transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18154767" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Effect of graft steatosis on liver function and organ survival after liver transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20583086" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : The biopsied donor liver: incorporating macrosteatosis into high-risk donor assessment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9697915" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Donor liver selection. The South-Eastern Organ Procurement Foundation Liver Committee.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8610352" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : The deleterious effect of donor high plasma sodium and extended preservation in liver transplantation. A multivariate analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10083179" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Use of high-risk liver donors for urgent and elective liver transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1926428" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Importance of donor blood chemistry data (AST, serum sodium) in predicting liver transplant outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1738933" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : The use of marginal donors for liver transplantation. A retrospective study of 365 liver donors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7489985" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Effect of donor age and sex on the outcome of liver transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8990363" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Influence of donor and recipient gender on the outcome of liver transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9753339" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Gender matching and outcome after pediatric liver transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9414778" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Impact of donor and recipient gender on liver transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1975036" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Liver transplantation across ABO blood group barriers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10968434" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Normalised intrinsic mortality risk in liver transplantation: European Liver Transplant Registry study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22874840" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Safety of blood group A2-to-O liver transplantation: an analysis of the United Network of Organ Sharing database.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7709460" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Successful use of an enhanced immunosuppressive protocol with plasmapheresis for ABO-incompatible mismatched grafts in liver transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10915175" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Acceptance of an ABO-incompatible mismatched (AB(+) to O(+)) liver allograft with the use of daclizumab and mycophenolate mofetil.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23928408" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : ABO-incompatible living donor liver transplantation is suitable in patients without ABO-matched donor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36749821" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Risk factors for antibody-mediated rejection in ABO blood-type incompatible and donor-specific antibody-positive liver transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2031256" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Effect of cold ischemia time on the early outcome of human hepatic allografts preserved with UW solution.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1360089" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Effect of extended cold ischaemia with UW solution on graft function after liver transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1417184" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Biliary strictures complicating liver transplantation. Incidence, pathogenesis, management, and outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16539636" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Characteristics associated with liver graft failure: the concept of a donor risk index.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23931659" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : The difficulty in defining extended donor criteria for liver grafts: the Eurotransplant experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11015091" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Liver transplantation from controlled non-heart-beating donors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11063334" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Controlled non-heart-beating donor liver transplantation: a successful single center experience, with topic update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15478896" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Donation after cardiac death: the University of Wisconsin experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21475025" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Biliary complications after liver transplantation from donation after cardiac death donors: an analysis of risk factors and long-term outcomes from a single center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21837741" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Events in procurement as risk factors for ischemic cholangiopathy in liver transplantation using donation after cardiac death donors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24002984" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Outcomes of transplantation of livers from donation after circulatory death donors in the UK: a cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21930997" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Liver transplantation using organ donation after cardiac death: a clinical predictive index for graft failure-free survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32216008" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Perioperative and long-term outcomes of utilizing donation after circulatory death liver grafts with macrosteatosis: A multicenter analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33222386" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Comparable graft survival is achievable with the usage of donation after circulatory death liver grafts from donors at or above 70 years of age: A long-term UK national analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29155020" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : The UK DCD Risk Score: A new proposal to define futility in donation-after-circulatory-death liver transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28645651" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Post-transplant cholangiopathy: Classification, pathogenesis, and preventive strategies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33626249" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Warming Up to Cold Perfusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22703372" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Asystole to cross-clamp period predicts development of biliary complications in liver transplantation using donation after cardiac death donors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28276658" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Safety and Outcomes in 100 Consecutive Donation After Circulatory Death Liver Transplants Using a Protocol That Includes Thrombolytic Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30929303" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Expanding the Donor Pool With the Use of Extended Criteria Donation After Circulatory Death Livers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18044778" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Biliary complications and outcomes of liver transplantation from donors after cardiac death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33626248" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Hypothermic Machine Perfusion in Liver Transplantation - A Randomized Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29369470" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Hypothermic oxygenated machine perfusion reduces bile duct reperfusion injury after transplantation of donation after circulatory death livers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28027600" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Comparison of longterm outcomes and quality of life in recipients of donation after cardiac death liver grafts with a propensity-matched cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33098277" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Liver Transplantation Using Hepatitis C Virus-Viremic Donors Into Hepatitis C Virus-Aviremic Recipients as Standard of Care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33188903" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Outcomes following liver transplantation from HCV-seropositive donors to HCV-seronegative recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22027583" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Liver transplantation from hepatitis B surface antigen positive donors: a safe way to expand the donor pool.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24142889" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Use of hepatitis B surface antigen-positive grafts in liver transplantation: a matched analysis of the US National database.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16035057" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Transplantation of hepatitis B surface antigen-positive livers into hepatitis B virus-positive recipients and the role of hepatitis delta coinfection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30342115" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Outcomes of DCD liver transplantation using organs treated by hypothermic oxygenated perfusion before implantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26752191" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Liver Transplantation After Ex Vivo Normothermic Machine Preservation: A Phase 1 (First-in-Man) Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27192971" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Transplantation of Declined Liver Allografts Following Normothermic Ex-Situ Evaluation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19958323" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Hypothermic machine preservation in human liver transplantation: the first clinical series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36681160" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : A multicenter randomized-controlled trial of hypothermic oxygenated perfusion (HOPE) for human liver grafts before transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15273542" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31592808" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Novel Real-time Prediction of Liver Graft Function During Hypothermic Oxygenated Machine Perfusion Before Liver Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27639262" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Preliminary Single-Center Canadian Experience of Human Normothermic Ex Vivo Liver Perfusion: Results of a Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37389552" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Normothermic Machine Perfusion of Donor Livers for Transplantation in the United States: A Randomized Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20677285" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12360426" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Optimizing the use of donated cadaver livers: analysis and policy development to increase the application of split-liver transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21931003" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Outcomes with split liver transplantation in 106 recipients: the University of California, San Francisco, experience from 1993 to 2010.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23108123" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Feasibility of split liver transplantation for 2 adults in the model of end-stage liver disease era.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28657945" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Expanding the Margins: High Volume Utilization of Marginal Liver Grafts Among&gt;2000 Liver Transplants at a Single Institution.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
